These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1906 related articles for article (PubMed ID: 34645374)

  • 1. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
    Kumari M; Lu RM; Li MC; Huang JL; Hsu FF; Ko SH; Ke FY; Su SC; Liang KH; Yuan JP; Chiang HL; Sun CP; Lee IJ; Li WS; Hsieh HP; Tao MH; Wu HC
    J Biomed Sci; 2022 Sep; 29(1):68. PubMed ID: 36096815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
    Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
    Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.
    Wang MY; Zhao R; Gao LJ; Gao XF; Wang DP; Cao JM
    Front Cell Infect Microbiol; 2020; 10():587269. PubMed ID: 33324574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19.
    Ameratunga R; Mears E; Leung E; Snell R; Woon ST; Kelton W; Medlicott N; Jordan A; Abbott W; Steele R; Rolleston W; Longhurst H; Lehnert K
    Clin Exp Immunol; 2023 Dec; 214(3):289-295. PubMed ID: 37565297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
    Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
    Dinda B; Dinda M; Dinda S; De UC
    Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.
    Sanna V; Satta S; Hsiai T; Sechi M
    Eur J Med Chem; 2022 Mar; 231():114121. PubMed ID: 35114539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.